Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma.
IDH-wildtype
extent of resection
glioblastoma
radiotherapy
surgery
tumor progression
tumor residuals
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
31
12
2022
revised:
23
02
2023
accepted:
10
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
In newly diagnosed IDH-wildtype glioblastoma, the frequency and prognostic relevance of tumor regrowth between resection and the initiation of adjuvant radiochemotherapy are unclear. In this retrospective single-center study we included 64 consecutive cases, for whom magnetic resonance imaging (MRI) was available for both the volumetric assessment of the extent of resection immediately after surgery as well as the volumetric target delineation before the initiation of adjuvant radiochemotherapy (time interval: 15.5 ± 1.9 days). Overall, a median new contrast-enhancement volume was seen in 21/64 individuals (33%, 1.5 ± 1.5 cm
Identifiants
pubmed: 36980633
pii: cancers15061745
doi: 10.3390/cancers15061745
pmc: PMC10046652
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Neuropathol. 2018 Aug;136(2):181-210
pubmed: 29967940
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
Neuro Oncol. 2022 Aug 12;:
pubmed: 35961053
Neuro Oncol. 2019 Feb 14;21(2):274-284
pubmed: 29893965
Radiother Oncol. 2016 Jan;118(1):35-42
pubmed: 26777122
Neurooncol Adv. 2022 Jun 04;4(1):vdac075
pubmed: 35769410
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
J Neurooncol. 2017 Apr;132(2):249-254
pubmed: 28101701
Neurooncol Adv. 2022 Sep 29;4(1):vdac158
pubmed: 36325373
J Neurooncol. 2013 Jan;111(2):177-85
pubmed: 23264191
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
J Neurooncol. 2018 Sep;139(3):671-678
pubmed: 29808339
J Neurooncol. 2017 Aug;134(1):169-175
pubmed: 28547592
Am J Clin Oncol. 2019 May;42(5):481-486
pubmed: 30973372
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Neurosurgery. 2012 Jan;70(1):234-43; discussion 243-4
pubmed: 21593697
J Neuropathol Exp Neurol. 2016 May;75(5):408-14
pubmed: 26975364
Diagnostics (Basel). 2020 Sep 05;10(9):
pubmed: 32899528
Neuro Oncol. 2009 Dec;11(6):842-52
pubmed: 19229057
PLoS One. 2015 Oct 26;10(10):e0141153
pubmed: 26502297
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95
pubmed: 36196752
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
J Neurooncol. 2022 Jan;156(2):317-327
pubmed: 34902093
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Front Oncol. 2021 Dec 13;11:748691
pubmed: 34966669
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
JAMA Oncol. 2020 Apr 1;6(4):495-503
pubmed: 32027343